XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Income and Other Comprehensive Income (Loss) ( Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues $ 42,692 $ 32,126 $ 74,608 $ 62,499
Cost of products sold 32,104 24,480 56,584 47,895
Gross profit 10,588 7,646 18,024 14,604
Operating expenses:        
Research and development 1,778 1,672 3,810 3,529
Selling, general and administrative 5,145 5,181 10,523 10,577
Total operating expenses 6,923 6,853 14,333 14,106
Operating income 3,665 793 3,691 498
Other income (expense):        
Interest and financing expense (440) (177) (864) (311)
Miscellaneous income 1,498 62 1,428 79
Total other income (expense) 1,058 (115) 564 (232)
Income before income taxes 4,723 678 4,255 266
Income tax provision (benefit) 1,375 170 1,242 (81)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3,348 508 3,013 347
Net income (loss) attributable to non-controlling interest 8 (4) 19 3
Net income attributable to Ultralife Corporation 3,340 512 2,994 344
Other comprehensive income (loss):        
Foreign currency translation adjustments (293) (1,262) (96) (1,498)
Comprehensive income (loss) attributable to Ultralife Corporation $ 3,047 $ (750) $ 2,898 $ (1,154)
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.21 $ 0.03 $ 0.19 $ 0.02
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.21 $ 0.03 $ 0.19 $ 0.02
Weighted average shares outstanding – basic (in shares) 16,141 16,129 16,138 16,116
Potential common shares (in shares) 3 20 3 25
Weighted average shares outstanding - diluted (in shares) 16,144 16,149 16,141 16,141